NDA 209478 · Cmp Dev LLC
Carospir
Spironolactone · Oral · Aldosterone Antagonist
OrphanLast checked: Nov 20, 2026Latest source record: Aug 24, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Aug 4, 2017
Approved uses
1
Original approval plus efficacy supplements
Registered trials
286
52 Phase 3, 28 recruiting
FAERS reports
114,068
86,569 serious, 13,594 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 28, 2026.
Spironolactone oral suspension is an antagonist of aldosterone indicated for: the treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure ( 1.1 ) use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.2 ) the management of edema in adult cirrhotic patients when edema is not responsive to fluid and sodium restrictions ( 1.3 ) 1.1 Heart Failure Spironolactone oral suspension is indicated for treatment of NYHA Class III-IV heart failure and reduced ejection fraction in adult patients to increase survival, manage edema, and to reduce the need for hospitalization for heart failure. Spironolactone oral suspension is usually administered in conjunction with other heart failure therapies. 1.2 Hypertension Spironolactone oral suspension is indicated as an add-on therapy for the treatment of hypertension, to lower blood pressure in adult patients who are not adequately controlled on other agents. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management,...
Mechanism: Spironolactone and its active metabolites are specific pharmacologic antagonists of aldosterone, acting primarily through competitive binding of receptors at the aldosterone-dependent sodium-potassium exchange site in the distal convoluted renal tubule. Spironolactone causes increased amounts of sodium and water to be excreted, while potassium is retained. Spironolactone acts both as a diuretic and as an antihypertensive drug by this mechanism. It may be given alone or with other diuretic agents that act more proximally in the renal tubule.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- CAROSPIR · SPIRONOLACTONE 25MG/5ML · SUSPENSION, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Spironolactone" as an intervention, any sponsor and status, largest first.
Centro Neurológico de Pesquisa e Reabiitação, BrazilAcademic, hospital or other
NCT03147092 · 15,000 participants (planned) · Start Feb 1, 2018 · Primary completion Jun 30, 2020
Drug: Captopril 25Mg, Hydrochlorothiazide 25Mg Oral Tablet,; Atenolol and 2 more · For: Hypertension; Blood Pressure
- Effect of MRA on Cardiovascular Disease in Patients With Hypertension and HyperaldosteronemiaPivotal-lookingEnrolling by invitation
Nanfang LiAcademic, hospital or other
NCT05688579 · 8,000 participants (planned) · Start Apr 16, 2023 · Primary completion Dec 31, 2026
Drug: Mineralocorticoid Receptor Antagonists(MRAs) · For: Hypertension; Hyperaldosteronaemia
Sites: Ürümqi, China
- Colchicine and Spironolactone in Patients with MI / SYNERGY Stent RegistryPivotal-lookingCompleted
Population Health Research InstituteAcademic, hospital or other
NCT03048825 · 7,264 participants · Start Feb 1, 2018 · Primary completion Aug 9, 2024
Drug: Colchicine; Spironolactone and 2 more · For: ST Elevation Myocardial Infarction; Non ST Elevation Myocardial Infarction
Sites: Bakersfield, California; Washington D.C., District of Columbia; Chicago, Illinois · 109 sites in all
- A Registry-based Cluster Randomized Trial to Compare the Effect of Spironolactone vs. Eplerenone on Clinical Outcomes in Patients With Symptomatic Systolic Heart FailurePivotal-lookingEnrolling by invitation
Bispebjerg HospitalAcademic, hospital or other
NCT03984591 · 7,200 participants (planned) · Start Nov 1, 2020 · Primary completion Dec 31, 2028
Drug: Eplerenone; Spironolactone · For: Systolic Heart Failure
Sites: Copenhagen, Denmark
- Recurrent Stroke Prevention Clinical Outcome StudyPivotal-lookingStatus unknown
Biomedis International Ltd.Academic, hospital or other
NCT01198496 · 5,000 participants (planned) · Start Oct 2010 · Primary completion Dec 2017
Drug: Losartan, Losartan and HCTZ, Amlodipine , Spironolactone · For: Hypertension; Stroke; Blood Pressure
Sites: Shimotsuke, Japan
- Standard Drug Therapy vs. Implanted Defibrillator for Primary Prevention of Sudden Cardiac DeathPivotal-lookingTerminated
Unity Health TorontoAcademic, hospital or other
NCT00524862 · 5,000 participants (planned) · Start Oct 2007 · Primary completion Apr 2011
Drug: Optimized medical therapy · For: Coronary Heart Disease; Congestive Heart Failure; Ventricular Dysfunction and 2 more
Sites: Hamilton, Canada; Kingston, Canada; London, Canada · 10 sites in all
- Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic FunctionPivotal-lookingCompleted
Carelon ResearchAcademic, hospital or other
NCT00094302 · 3,445 participants · Start Aug 2006 · Primary completion Jun 2013
Drug: Spironolactone; Placebo · For: Cardiovascular Diseases; Heart Diseases; Heart Failure, Congestive
Sites: Birmingham, Alabama; Glendale, Arizona; Phoenix, Arizona · 270 sites in all
- Key Diagnostic & Therapeutic Technologies for Severe Acute High Altitude Disease (SAHAD): Integration and ApplicationPivotal-lookingNot yet recruiting
Tibet Autonomous Region People's HospitalAcademic, hospital or other
NCT07639931 · 3,035 participants (planned) · Start Jul 1, 2026 · Primary completion Dec 20, 2028
Drug: Multicenter study of HAPE group:NO Group · For: Severe High Altitude Pulmonary Edema; Severe High Altitude Cerebral Edema
Sites: Lhasa, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea9,056
- fatigue7,400
- nausea6,911
- diarrhoea6,535
- acute kidney injury5,703
- dizziness5,651
- headache5,543
- off label use5,180
- drug ineffective4,907
- hypotension4,890
- fall4,218
- death4,158
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 925 |
| 2005 | 1,121 |
| 2006 | 1,073 |
| 2007 | 1,069 |
| 2008 | 1,201 |
| 2009 | 1,459 |
| 2010 | 1,968 |
| 2011 | 2,150 |
| 2012 | 2,739 |
| 2013 | 2,708 |
| 2014 | 3,550 |
| 2015 | 5,261 |
| 2016 | 6,809 |
| 2017 | 6,304 |
| 2018 | 7,722 |
| 2019 | 8,404 |
| 2020 | 7,887 |
| 2021 | 7,806 |
| 2022 | 7,969 |
| 2023 | 8,769 |
| 2024 | 9,708 |
| 2025 | 9,761 |
| 2026 | 7,704 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Carospir (Spironolactone)
2024 spending
$186K
Beneficiaries
91
291 claims
Per beneficiary
$2,044
$3.35 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $235,444 |
| 2021 | $355,190 |
| 2022 | $475,186 |
| 2023 | $567,507 |
| 2024 | $186,000 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Spironolactone vs Amiloride for Resistant Hypertension: A Randomized Clinical Trial.
Lee CJ, Ihm SH, Shin DH, et al. · JAMA 2025 · Clinical Trial, Phase IV, Comparative Study
- Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.
Williams B, MacDonald TM, Morant S, et al. · Lancet 2015 · Comparative Study, Randomized Controlled Trial
- Spironolactone for heart failure with preserved ejection fraction.
Pitt B, Pfeffer MA, Assmann SF, et al. · N Engl J Med 2014 · Multicenter Study, Randomized Controlled Trial
- The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
Pitt B, Zannad F, Remme WJ, et al. · N Engl J Med 1999 · Clinical Trial, Multicenter Study
- Routine Spironolactone in Acute Myocardial Infarction.
Jolly SS, d'Entremont MA, Pitt B, et al. · N Engl J Med 2025 · Clinical Trial, Phase III, Multicenter Study
- Efficacy of pharmacological and interventional treatment for resistant hypertension: a network meta-analysis.
Tian Z, Vollmer Barbosa C, Lang H, et al. · Cardiovasc Res 2024 · Systematic Review, Network Meta-Analysis
Sponsor: Cmp Dev LLC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.